SCHEMBL25339693

SCHEMBL25339693

CCOC(=O)c1cnn2ccc(N3CCO[C@H](C)C3)nc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
TGFBR1 P36897 3/20 0.42
SMPD3 Q9NY59 6/20 0.41
GSK3A P49840 5/20 0.41
IRAK4 Q9NWZ3 2/20 0.41
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 4/20 0.39
PIM1 P11309 1/20 0.38
CDK2 P24941 1/20 0.38
GSK3B P49841 1/20 0.38
CDK5 Q00535 1/20 0.38
PRKCQ Q04759 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
NR3C2 P08235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25968638 1.00 FLT3 (0.42) FLT3ALDH1A1MEN1GAAKMT2A
SCHEMBL23744970 1.00 FLT3 (0.42) FLT3ALDH1A1MEN1GAAKMT2A
SCHEMBL25861503 0.89 CHEK1 (0.43) FLT3TGFBR1SMPD3IRAK4
SCHEMBL25861566 0.89 CHEK1 (0.43) FLT3TGFBR1SMPD3IRAK4
SCHEMBL21997871 0.88 ALDH1A1 (0.52) ALDH1A1MEN1GAAKMT2ATGFBR1
SCHEMBL21998006 0.88 ALDH1A1 (0.52) ALDH1A1MEN1GAAKMT2ATGFBR1
SCHEMBL25968662 0.88 ALDH1A1 (0.52) ALDH1A1MEN1GAAKMT2ATGFBR1
SCHEMBL23744414 0.88 ALDH1A1 (0.52) ALDH1A1MEN1GAAKMT2ATGFBR1
SCHEMBL21998070 0.88 ALDH1A1 (0.52) ALDH1A1MEN1GAAKMT2ATGFBR1
SCHEMBL25861568 0.88 IRAK4 (0.43) FLT3TGFBR1SMPD3IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-09 US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 EP disclosed
US-12091411-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-17 US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 US disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FLT3 60/4885ALDH1A1 2776/4885MEN1 4055/4885
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FLT3 60/4885ALDH1A1 2776/4885MEN1 4055/4885
US-12091411-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 FLT3 60/4885ALDH1A1 2776/4885MEN1 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.